Atul Malhotra, MD, a sleep medicine specialist at UC San Diego Health, and co-authors conducted two phase 3, double-blind, randomized controlled trials for tirzepatide in moderate-to-severe OSA patients with obesity who were and were not using CPAP
Im grateful to have worked with a fantastic study team and collaborators on this important question
It may cause dehydration, nutrient loss, and fatigue, especially if it continues over time
A pooled analysis of randomised controlled trials confirmed the efficacy and safety of Retatrutide as a GLP-1, GIP, and glucagon receptor agonist for obesity treatment across the studied dose range
How is pricing handled and is my information private
Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9)